The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients

Creative Commons License

ERTÜRK Ş., Nergizoglu G., Ates K., Duman N., Erbay B., Karatan O., ...Daha Fazla

NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.14, sa.8, ss.1912-1916, 1999 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 8
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1093/ndt/14.8.1912
  • Dergi Adı: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1912-1916
  • Anahtar Kelimeler: ACE inhibitors, anaemia, erythropoietin, haemodialysis, hypertension, left ventricular hypertrophy, RECOMBINANT-HUMAN-ERYTHROPOIETIN, CONVERTING ENZYME-INHIBITOR, CHRONIC-RENAL-FAILURE, CHRONIC-HEMODIALYSIS PATIENTS, TRANSPLANT RECIPIENTS, HYPERTENSIVE PATIENTS, SERUM ERYTHROPOIETIN, RECEPTOR ANTAGONIST, DIALYSIS PATIENTS, BLOOD-PRESSURE
  • Ankara Üniversitesi Adresli: Evet

Özet

Background. Aagiotensin-converting enzyme (ACE) inhibitors have the capability of decreasing left ventricular mass index (LVMI) in chronic haemodialysis (HD) patients. On the other hand, recent reports provide conflicting information regarding the impact of ACE inhibitors on responsiveness to recombinant human erythropoietin (rHuEpo), and there are no data about the effect of withdrawing ACE inhibitors both on rHuEpo response and LVMI in HD patients.